Bradley Bertram, MD
Ophthalmology · Augusta, GANPI 1184785008
Payments from drug & device makers
Across 332 payments — averaging $46.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akorn Operating Company LLC$5K
- Alcon$3K
- Sun Pharmaceutical Industries Inc.$1K
- Glaukos Corporation$1K
- AbbVie$842
- Ivantis, Inc$532
- plus $4K from 28 others
What the payments were for
- Consulting fees$5,00032%
- Food & beverage$10,38367%
- Education$1821%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akorn Operating Company LLC | 1 | $5,000 |
| Alcon | 76 | $2,943 |
| Sun Pharmaceutical Industries Inc. | 59 | $1,224 |
| Glaukos Corporation | 19 | $1,045 |
| AbbVie(2 entities) | 32 | $842 |
| Ivantis, Inc | 15 | $532 |
| Kala Pharmaceuticals, Inc. | 18 | $505 |
| NEW World Medical,inc. | 4 | $464 |
| Mallinckrodt Hospital Products Inc. | 10 | $390 |
| Bausch & Lomb Americas Inc. | 17 | $373 |
| Novartis | 15 | $359 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $237 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $211 |
| Oyster Point Pharma, Inc. | 4 | $196 |
| Eyevance Pharmaceuticals LLC | 3 | $154 |
| Johnson & Johnson Vision Care, Inc. | 2 | $137 |
| Harrow Eye, LLC | 5 | $128 |
| Biotissue Holdings Inc. | 3 | $108 |
| Genentech, Inc. | 1 | $105 |
| Sight Sciences, Inc. | 6 | $102 |
| Tarsus Pharmaceuticals, Inc. | 5 | $88 |
| Shire North American Group Inc | 4 | $85 |
| Dompe US, Inc. | 3 | $61 |
| Ocular Therapeutix, Inc. | 3 | $40 |
| Amgen(2 entities) | 2 | $36 |
| Carl Zeiss Meditec USA, Inc. | 1 | $33 |
| Iridex Corporation | 1 | $30 |
| Omeros Corporation | 2 | $25 |
| Carl Zeiss Meditec, Inc. | 1 | $22 |
| Eyepoint US, Inc. | 1 | $20 |
| Thea Pharma Inc. | 1 | $18 |
| Quidel Corporation | 1 | $18 |
| Rxsight Inc | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$568
- Centurion$418
- Hydrus Microstent$371
- Kahook Dual Blade$329
- Streamline Surgical System$329
- Ahmed Glaucoma Valve$329
- iStent inject W$290
- KXL System$290
- CEQUA$245
- ARGOS$234
- IACCESS$158
- Photrexa$158
- TYRVAYA$150
- iStent$132
- XIIDRA$125
- EYSUVIS$125
- Zerviate$118
- Acuvue$115
- ACTHAR$114
- VYZULTA$110
How this compares
$15,565 in reported general payments places this provider in the 85th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 65 | $59,666 |
| LumiganBimatoprost | 99 | $47,749 |
| VyzultaLatanoprostene Bunod | 71 | $35,009 |
| CombiganBrimonidine Tartrate/Timolol | 49 | $17,732 |
| Prednisolone Acetate | 359 | $17,463 |
| Latanoprost | 1,036 | $15,983 |
| Cyclosporine | 29 | $14,844 |
| XiidraLifitegrast | 17 | $14,159 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 48 | $10,653 |
| Fluorometholone | 109 | $8,867 |
| ProlensaBromfenac Sodium | 18 | $6,416 |
| Gatifloxacin | 101 | $5,265 |
| Timolol Maleate | 502 | $5,029 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $3,583 |
| Bromfenac Sodium | 24 | $3,243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $842 | $125,147213 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $373 | $49,16888 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $211 | $8,08132 claims |
| AlconSimbrinza | $2,943 | $3,58311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Augusta
- Dennis MarcusAugusta$9.2M
- Robert StoltzMarietta$3.9M
- Eugene McLaurinSavannah$3.3M
- Clayton BlehmGainesville$1.7M
- Lakshmana KooragayalaMarietta$1.4M
- Douglas DayAtlanta$1.1M
- Jennifer KimMorrow$989K
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
- Lawrence WoodardAtlanta$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.